中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Metabolic Diseases
Immune Diseases
Exploratory Indications
Pipeline
Pipeline
Clinical Trials
Partnership
Investors
Financials & Filing
Upcoming Events
Presentations
News
Careers
Our Focus
Metabolic Diseases
Immune Diseases
Exploratory Indications
Boyle, JG, et al., Clinical Science (2018) 132 1699–1709
Publications
Title
Venue
Type
Date
GLP-1R/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice
ObesityWeek® 2025
Poster
11/2025
A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity
ObesityWeek® 2025
Poster
11/2025
ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity:A Ph Ib Study
ObesityWeek® 2025
Poster
11/2025
ASC30, an Oral GLP-1R Biased Small Molecule Agonist Demonstrated Superior Weigh Loss in Participants with Obesity: A 28-Day Multiple Ascending Dose Study
The 61st European Association for the Study of Diabetes
(EASD 2025)
Short Oral Presentation
9/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model
The American Diabetes Association's 85th Scientific Sessions
(ADA 2025)
Poster
6/2025
ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study
The American Diabetes Association's 85th Scientific Sessions
(ADA 2025)
Poster
6/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study
The 32nd European Congress On Obesity (ECO 2025)
Guided poster
5/2025
ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO Mice
The 32nd European Congress On Obesity (ECO 2025)
Oral
5/2025
浙公网安备 33010802003344号
浙ICP备11050387号-1